Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Dirk T. Haselow is active.

Publication


Featured researches published by Dirk T. Haselow.


Pediatrics | 2006

One Dose of Varicella Vaccine Does Not Prevent School Outbreaks: Is it Time for a Second Dose?

Adriana S. Lopez; Dalya Guris; Laura Zimmerman; Linda Gladden; Tamara Moore; Dirk T. Haselow; Vladimir N. Loparev; D. Scott Schmid; Aisha O. Jumaan; Sandra Snow

OBJECTIVES. The implementation of a routine childhood varicella vaccination program in the United States in 1995 has resulted in a dramatic decline in varicella morbidity and mortality. Although disease incidence has decreased, outbreaks of varicella continue to be reported, increasingly in highly vaccinated populations. In 2000, a varicella vaccination requirement was introduced for kindergarten entry in Arkansas. In October 2003, large numbers of varicella cases were reported in a school with high vaccination coverage. We investigated this outbreak to examine transmission patterns of varicella in this highly vaccinated population, to estimate the effectiveness of 1 dose of varicella vaccine, to identify risk factors for vaccine failure, and to implement outbreak control measures. METHODS. A retrospective cohort study involving students attending an elementary school was conducted. A questionnaire was distributed to parents of all of the students in the school to collect varicella disease and vaccination history; parents of varicella case patients were interviewed by telephone. A case of varicella was defined as an acute, generalized, maculopapulovesicular rash without other apparent cause in a student or staff member in the school from September 1 to November 20, 2003. Varicella among vaccinated persons was defined as varicella-like rash that developed >42 days after vaccination. In vaccinated persons, the rash may be atypical, maculopapular with few or no vesicles. Cases were laboratory confirmed by polymerase chain reaction, and genotyping was performed to identify the strain associated with the outbreak. RESULTS. Of the 545 students who attended the school, 88% returned the questionnaire. Overall varicella vaccination coverage was 96%. Forty-nine varicella cases were identified; 43 were vaccinated. Three of 6 specimens tested were positive by polymerase chain reaction. The median age at vaccination of vaccinated students in the school was 18 months, and the median time since vaccination was 59 months. Forty-four cases occurred in the East Wing, where 275 students in grades kindergarten through 2 were located, and vaccination coverage was 99%. In this wing, varicella attack rates among unvaccinated and vaccinated students were 100% and 18%, respectively. Vaccine effectiveness against varicella of any severity was 82% and 97% for moderate/severe varicella. Vaccinated cases were significantly milder compared with unvaccinated cases. Among the case patients in the East Wing, the median age at vaccination was 18.5 and 14 months among non–case patients. Four cases in the West Wing did not result in further transmission in that wing. The Arkansas strains were the same as the common varicella-zoster virus strain circulating in the United States (European varicella-zoster virus strain). CONCLUSIONS. Although disease was mostly mild, the outbreak lasted for ∼2 months, suggesting that varicella in vaccinated persons was contagious and that 99% varicella vaccination coverage was not sufficient to prevent the outbreak. This investigation highlights several challenges related to the prevention and control of varicella outbreaks with the 1-dose varicella vaccination program and the need for further prevention of varicella through improved vaccine-induced immunity with a routine 2-dose vaccination program. The challenges include: 1-dose varicella vaccination not providing sufficient herd immunity levels to prevent outbreaks in school settings where exposure can be intense, the effective transmission of varicella among vaccinated children, and the difficulty in the diagnosis of mild cases in vaccinated persons and early recognition of outbreaks for implementing control measures. The efficacy of 2 doses of varicella vaccine compared with 1 dose was assessed in a trial conducted among healthy children who were followed for 10 years. The efficacy for 2 doses was significantly higher than for 1 dose of varicella vaccine. This higher efficacy translated into a 3.3-fold lower risk of developing varicella >42 days after vaccination in 2- vs 1-dose recipients. Of the children receiving 2 doses, 99% achieved a glycoprotein-based enzyme-linked immunosorbent assay level of ≥5 units (considered a correlate of protection) 6 weeks after vaccination compared with 86% of children who received 1 dose. The 6-week glycoprotein-based enzyme-linked immunosorbent assay level of ≥5 units has been shown to be a good surrogate for protection from natural disease. Ten years after the implementation of the varicella vaccination program, disease incidence has declined dramatically, and vaccination coverage has increased greatly. However, varicella outbreaks continue to occur among vaccinated persons. Although varicella disease among vaccinated persons is mild, they are contagious and able to sustain transmission. As a step toward better control of varicella outbreaks and to reduce the impact on schools and public health officials, in June 2005, the Advisory Committee on Immunization Practices recommended the use of a second dose of varicella vaccine in outbreak settings. Early recognition of outbreaks is important to effectively implement a 2-dose vaccination response and to prevent more cases. Although the current recommendation of providing a second dose of varicella vaccine during an outbreak offers a tool for controlling outbreaks, a routine 2-dose recommendation would be more effective at preventing cases. Based on published data on immunogenicity and efficacy of 2 doses of varicella vaccine, routine 2-dose vaccination will provide improved protection against disease and further reduce morbidity and mortality from varicella.


Journal of Toxicology and Environmental Health | 2001

GASTROINTESTINAL AND RESPIRATORY TRACT SYMPTOMS FOLLOWING BRIEF ENVIRONMENTAL EXPOSURE TO AEROSOLS DURING A PFIESTERIA-RELATED FISH KILL

Dirk T. Haselow; Ernest G. Brown; J. Kathleen Tracy; Robert Magnien; Lynn M. Grattan; J. Glenn Morris; David Oldach

An outbreak of illness with flulike symptoms among state workers responding to a Pfiesteria bloom that resulted in fish death and distress on the Chicamacomico River on Marylands Eastern Shore was investigated. Using case-control methodology, seven workers present at the Chicamacomico were compared to seven occupationally matched controls not present. Participants completed questionnaires assessing their exposures to water and their symptom histories and were assessed with a standard neuropsychological test battery. Three months later, the same questionnaires and neuropsychological tests were repeated. Three of the seven exposed workers cited minimal direct contact with water and four cited none. During the event, four developed burning eyes or nares and six developed a headache or sore throat. Six developed crampy abdominal pain, nausea, or diarrhea within 4 h of their exposure. In contrast, the only aforementioned symptom reported by controls was headache in two individuals. Acute and follow-up neuropsychological tests showed no consistent pattern of deficiency among the exposed. In conclusion, a flulike clinical illness was observed following exposure to a Pfiesteria -related fish kill, possibly as a result of inhalation of toxic aerosols.


Emerging Infectious Diseases | 2015

Cluster of Cryptococcus neoformans Infections in Intensive Care Unit, Arkansas, USA, 2013.

Snigdha Vallabhaneni; Dirk T. Haselow; Spencer Lloyd; Shawn R. Lockhart; Heather Moulton-Meissner; Laura Lester; Gary Wheeler; Linda Gladden; Kelley Garner; Gordana Derado; Benjamin Park; Julie R. Harris

Use of short-term steroids was a risk factor for infection.


Emerging Infectious Diseases | 2012

Geographic distribution of endemic fungal infections among older persons, United States.

Dirk T. Haselow; Michael Saccente; Keyur Vyas; Ryan Bariola; Haytham Safi; Robert W. Bradsher; Nate Smith; James Phillips

To the Editor: We read with interest the article by Baddley et al. (1) and appreciate their efforts to characterize incidence rates of mycoses. We agree that histoplasmosis, blastomycosis, and coccidioidomycosis are differential diagnoses for patients with consistent symptoms but who reside outside mycosis-endemic areas. However, we believe that the methods of Baddley et al. probably do not determine the true incidence of these mycoses in sparsely populated states such as Arkansas. Their estimates contrast markedly with surveillance data from the Arkansas Department of Health (Table) and with our clinical experience as infectious disease physicians. We characterize Arkansas as a state in which histoplasmosis and blastomycosis incidence is high and coccidioidomycosis incidence is low; however, Baddley et al. indicate that in Arkansas, incidence of blastomycosis is relatively low and incidence of coccidioidomycosis is high. Table Reported cases of fungal diseases in Arkansas, by year* To investigate whether this finding might be associated with their small 5% sample of Medicare beneficiaries, we used data from the Arkansas census to determine that in 2008 the population of adults >65 years of age was ≈407,014, and during 1999–2008, there were ≈3,840,896 person-years for persons in this age group. A 5% sample would account for ≈192,045 person-years. Using their rate ranges (7.84–12.3 cases/100,000 person-years for histoplasmosis, 3.97–6.71 for coccidioidomycosis, and 0.39–0.86 for blastomycosis), we calculated the approximate numbers of cases in their sample: 15–23 histoplasmosis cases, 7–12 coccidioidomycosis cases, and only 1 blastomycosis case. Compared with rates from surveillance averaged over the 10 years, the midpoints of the Baddley et al. estimates are ≈6-fold higher for histoplasmosis, ≈60-fold higher for coccidioidomycosis, and ≈0.4-fold lower for blastomycosis. Only their estimate for blastomycosis incidence falls within the 10-year 95% CIs from surveillance data. We believe that the small cell sizes require that the rate estimates of Baddley et al. be interpreted with care, especially with respect to less populous states.


Clinical Infectious Diseases | 2017

Possible Transfusion-Transmitted Babesia divergens–like/MO-1 Infection in an Arkansas Patient

Mary J. Burgess; Eric R. Rosenbaum; Bobbi S. Pritt; Dirk T. Haselow; Katie M. Ferren; Bashar Alzghoul; Juan Carlos Rico; Lynne M. Sloan; Poornima Ramanan; Raghunandan Purushothaman; Robert W. Bradsher

A patient with asplenia and multiple red blood cell transfusions acquired babesiosis infection with Babesia divergens-like/MO-1 organisms and not Babesia microti, the common United States species. He had no known tick exposure. This is believed to be the first transfusion-transmitted case and the fifth documented case of B. divergens-like/MO-1 infection.


Open Forum Infectious Diseases | 2014

Influenza A Outbreak in an Ambulatory Stem Cell Transplant Center

Senu Apewokin; Keyur Vyas; Laura Lester; Monica Grazzuitti; Dirk T. Haselow; Frankie Wolfe; Michelle Roberts; William T. Bellamy; Naveen Sanath Kumar; Dolris Hunter; Jeannette Y. Lee; Jennifer Laudadio; J. Gary Wheeler; Robert W. Bradsher

Background  In the era of cost-consciousness regarding healthcare , provision of medical services in an outpatient setting has become increasingly attractive. We report an influenza outbreak in an ambulatory stem cell transplant center in 2013 that highlights unique identification and infection control challenges in this setting. Methods  Nasopharyngeal swabs were performed on patients with suspected influenza-like illnesses (ILI), defined by subjective fever or measured temperature of ≥37.7°C (≥100°F) with cough or sore throat during July 25, 2013 through August 7, 2013. In addition, testing was triggered by an elevated C-reactive protein (CRP). Specimens were analyzed by using eSensor Respiratory Viral Panel. Clinical and epidemiologic information was collected in real time, and frequencies were calculated on demographics, baseline clinical parameters, treatment methods, comorbidities, and symptoms of affected persons. Results  Thirty-one patients had influenza A (H3N2) infection during July 25, 2013 through August 7, 2013. Only 7 patients (23%) met the Centers for Disease Control and Prevention and Council of State and Territorial Epidemiologists ILI case definition. Twenty-five patients (81%) had received ≥1 transplant, with 13 (42%) having occurred within 1 year before the outbreak. Twenty-five patients (81%) had received B-cell active chemotherapy <60 days before influenza diagnosis, 6 (19%) were neutropenic, and 25 (81%) lymphopenic. Among clinical and laboratory markers analyzed, abnormal CRP was the most sensitive screening tool for influenza. Twelve (39%) patients were hospitalized (median stay, 10 days; range, 2–20). No deaths occurred. Conclusions  Immunocompromised hosts with influenza have atypical presentations. Existing surveillance case definitions might be insufficient to reliably identify influenza outbreaks in such patients.


Open Forum Infectious Diseases | 2017

Variation in Tularemia Clinical Manifestations—Arkansas, 2009–2013

Laura K. Lester Rothfeldt; Richard F. Jacobs; J. Gary Wheeler; Susan Weinstein; Dirk T. Haselow

Abstract Background Francisella tularensis, although naturally occurring in Arkansas, is also a Tier 1 select agent and potential bioterrorism threat. As such, tularemia is nationally notifiable and mandatorily reported to the Arkansas Department of Health. We examined demographic and clinical characteristics among reported cases and outcomes to improve understanding of the epidemiology of tularemia in Arkansas. Methods Surveillance records on all tularemia cases investigated during 2009–2013 were reviewed. Results The analytic dataset was assembled from 284 tularemia reports, yielding 138 probable and confirmed tularemia cases during 2009–2013. Arthropod bite was identified in 77% of cases. Of 7 recognized tularemia manifestations, the typhoidal form was reported in 47% of cases, approximately double the proportion of the more classic manifestation, lymphadenopathy. Overall, 41% of patients were hospitalized; 3% died. The typhoidal form appeared to be more severe, accounting for the majority of sepsis and meningitis cases, hospitalizations, and deaths. Among patients with available antibiotic data, 88% received doxycycline and 12% received gentamicin. Conclusions Contrary to expectation, lymphadenopathy was not the most common manifestation observed in our registry. Instead, our patients were more likely to report only generalized typhoidal symptoms. Using lymphadenopathy as a primary symptom to initiate tularemia testing may be an insensitive diagnostic strategy and result in unrecognized cases. In endemic areas such as Arkansas, suspicion of tularemia should be high, especially during tick season. Outreach to clinicians describing the full range of presenting symptoms may help address misperceptions about tularemia.


Emerging Infectious Diseases | 2017

Multistate Epidemiology of Histoplasmosis, United States, 2011–20141

Paige Armstrong; Brendan R. Jackson; Dirk T. Haselow; Virgie Fields; Malia Ireland; Connie Austin; Kimberly Signs; Veronica Fialkowski; Reema Patel; Peggy Ellis; Peter C. Iwen; Caitlin Pedati; Suzanne N. Gibbons-Burgener; Jannifer Anderson; Thomas Dobbs; Sherri Davidson; Mary G. McIntyre; Kimberly Warren; Joanne Midla; Nhiem Luong; Kaitlin Benedict

Increased awareness could lead to appropriate diagnosis, prompt treatment, and better patient outcomes.


Telemedicine Journal and E-health | 2016

Mobilizing a Statewide Network to Provide Ebola Education and Support.

Sarah Rhoads; Bush E; Dirk T. Haselow; Keyur Vyas; Wheeler Jg; Faulkner A; Curtis L. Lowery

BACKGROUND Healthcare providers require the latest information and procedures when a public health emergency arises. During the fall of 2014, when the Ebola virus was first identified in a patient in the United States, education about Ebola virus disease (EVD) and procedures for its identification and control needed widespread and immediate dissemination to healthcare providers. In addition, there was a need to allay fears and reassure the public and providers that a process was in place to manage Ebola should it arrive in Arkansas. The state health department engaged multiple interest groups and provided a variety of educational and management activities. The Arkansas Department of Health and the only academic medical center in the state began offering time-consuming, one-on-one education over the phone, which reached too few providers. A solution was needed to educate many providers across the state in the protocols for identification, isolation, and management of patients with EVD. In response, the Arkansas Department of Health and the University of Arkansas for Medical Sciences leveraged the interactive video and Webinar capabilities of the states telemedicine network to educate both providers and the public of this public health emergency. MATERIALS AND METHODS Six interactive video events were staged over 5 days in October 2014. RESULTS In six events, 82 individual healthcare facilities (67 of which were hospitals) and 378 providers attended via the Webinar option, whereas 323 healthcare professionals received continuing education credits. CONCLUSIONS A statewide videoconferencing infrastructure can be successfully mobilized to provide timely public health education and communication to healthcare providers and the public in multiple disciplines and practice settings.


Emerging Infectious Diseases | 2018

Burkholderia thailandensis Isolated from Infected Wound, Arkansas, USA

Jay E. Gee; Mindy G. Elrod; Christopher A. Gulvik; Dirk T. Haselow; Catherine Waters; Lindy Liu; Alex R. Hoffmaster

The bacterium Burkholderia thailandensis, a member of the Burkholderia pseudomallei complex, is generally considered nonpathogenic; however, on rare occasions, B. thailandensis infections have been reported. We describe a clinical isolate of B. thailandensis, BtAR2017, recovered from a patient with an infected wound in Arkansas, USA, in 2017.

Collaboration


Dive into the Dirk T. Haselow's collaboration.

Top Co-Authors

Avatar

J. Gary Wheeler

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Kaitlin Benedict

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Keyur Vyas

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Laura Lester

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Robert W. Bradsher

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Alexandria Beebe

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Benjamin Park

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Brendan R. Jackson

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Connie Austin

Illinois Department of Public Health

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge